QLGN vs. MRSN, PLUR, XFOR, JSPR, OKUR, SNTI, RANI, MURA, ADAP, and EGRX
Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Mersana Therapeutics (MRSN), Pluri (PLUR), X4 Pharmaceuticals (XFOR), Jasper Therapeutics (JSPR), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), Rani Therapeutics (RANI), Mural Oncology (MURA), Adaptimmune Therapeutics (ADAP), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry.
Qualigen Therapeutics vs. Its Competitors
Mersana Therapeutics (NASDAQ:MRSN) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
Mersana Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
Mersana Therapeutics currently has a consensus price target of $56.60, indicating a potential upside of 583.57%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Mersana Therapeutics is more favorable than Qualigen Therapeutics.
93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 13.0% of Mersana Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Qualigen Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics.
Qualigen Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%.
In the previous week, Qualigen Therapeutics had 5 more articles in the media than Mersana Therapeutics. MarketBeat recorded 6 mentions for Qualigen Therapeutics and 1 mentions for Mersana Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.51 beat Mersana Therapeutics' score of 0.00 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.
Summary
Mersana Therapeutics beats Qualigen Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Qualigen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qualigen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:QLGN) was last updated on 10/3/2025 by MarketBeat.com Staff
